BRL-26830A
BRL-26830A is a β-adrenergic receptor agonist. BRL-26830A reduces body weight and increases metabolic rate in obese mouse models. BRL-26830A stimulates insulin release and significantly reduces blood glucose levels in ICR mouse models. BRL-26830A can be used to study endocrine and metabolic diseases such as obesity and diabetes[1][2][2].
Product Specifications
CAS Number
87857-42-9
UNSPSC
12352100
Target
Adrenergic Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Smiles
O=C(O)/C=C/C(O)=O.O=C(OC)C1=CC=C(C[C@@H](NC[C@@H](O)C2=CC=CC=C2)C)C=C1.[1/2]
Molecular Formula
C19H23NO3.1/2C4H4O4
Molecular Weight
371.45
References & Citations
[1]Connacher AA, et al. Clinical studies with the beta-adrenoceptor agonist BRL 26830A. Am J Clin Nutr. 1992 Jan;55 (1 Suppl) :258S-261S.|[2]Arch JR, et al. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr. 1983 Oct;38 (4) :549-58. |[3]Yoshida T. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin. Am J Clin Nutr. 1992 Jan;55 (1 Suppl) :237S-241S. d
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15246349 1 Vial
Lentiviral mouse Dtna shRNA (UAS) - Lentiviral mouse Dtna shRNA (UAS, RFP) plasmid
Sign In for Pricing
View Details 
